Ansell (ASX: ANN): Margin Expansion and Operational Resilience Through Transition
Ansell (ASX: ANN) delivers double‑digit earnings growth, disciplined cost control, and strong cash conversion amid subdued market conditions, reinforcing margin resilience and balance‑sheet strength.
Sigma Healthcare (ASX: SIG): Integrated Scale, Relentless Momentum
Sigma Healthcare (ASX: SIG) delivers strong double‑digit growth and disciplined integration, positioning the merged Chemist Warehouse group for sustained expansion across domestic and international markets
Lumos Diagnostics (ASX: LDX): Enters Its Proof Phase as LDX Breaks the Downtrend
Lumos Diagnostics continues to expand its commercial footprint through FDA clearance, growing U.S. adoption, manufacturing partnerships, and paediatric research. The company now focuses on turning regulatory success and market access into recurring sales, broader reimbursement, and sustainable long-term growth.
Healius (ASX: HLS): Sells Agilex Biolabs to Novotech for $160m to Sharpen Pathology Focus
Healius (ASX: HLS), founded in 1985, has agreed to sell Agilex Biolabs to Novotech for an enterprise value of $160 million, sharpening its focus on core pathology operations.
.webp&w=828&q=75)
Emyria (ASX: EMD): Sydney Clinic Opens as Treatment Network Expands
Emyria (ASX: EMD) has opened its first Sydney Empax clinic, expanding its treatment network to four Australian states. The new facility adds treatment capacity, while patient volumes and reimbursement arrangements remain key factors in its commercial development.
Racura Oncology (ASX: RAC): A High-Risk, High-Reward Oncology Play
Racura Oncology (ASX: RAC) is executing on a bold clinical strategy centered on RC220 (bisantrene reformulation), targeting both cardioprotection and enhanced anticancer activity in combination with doxorubicin. The company has dosed its first patient in a Phase 1 solid tumor trial, expanded into South Korea, and strengthened its clinical leadership team, all while maintaining disciplined cash management (A$13.67m at June 2025) to fund operations into 2026. Though early-stage, RAC presents a compelling mid- to long-term optionality scenario for investors with conviction in cardio-oncology and specialty chemotherapy.